How the consolidation of payers, PBMs, and specialty pharmacies is reshaping patient access.

The three largest pharmacy benefit managers in the United States now adjudicate roughly 80 percent of all prescription claims. Three wholesalers control approximately 98 percent of drug distribution. And every one of the dominant PBMs sits inside a vertically integrated parent company that also owns a health insurer and a pharmacy network.

This is not a new development. But in 2026, the structure is more consolidated, the regulatory pressure is more serious, and the consequences for specialty patients are more visible than they have ever been. If you manage specialty medications for patients, or if you are a patient trying to access one, the architecture of the PBM market is not an abstract policy question. It is the system you are operating inside.

What vertical integration actually means

A PBM started as a claims processor. It sat between the health plan and the pharmacy, adjudicating prescriptions, negotiating rebates with manufacturers, and managing formularies on behalf of plan sponsors. The function was administrative. The position was intermediary.

That description has not been accurate for years.

Today, the three largest PBMs, CVS Caremark, Express Scripts, and OptumRx, are not independent intermediaries. CVS Caremark operates inside CVS Health, which also owns Aetna and the CVS retail pharmacy chain. Express Scripts operates inside Cigna's Evernorth division, which also owns Accredo, one of the largest specialty pharmacies in the country. OptumRx operates inside UnitedHealth Group, alongside UnitedHealthcare and an expansive network of provider practices.

Each of these structures means the same entity that decides which drugs are covered, at what tier, and through which pharmacy also owns the pharmacy that benefits when patients are steered toward it. The intermediary became the destination.

The specialty pharmacy problem

Specialty medications are where the access consequences of vertical integration are most acute. Specialty drugs are expensive, they require specific handling and distribution infrastructure, and they are increasingly the category where PBMs generate the most revenue.

A January 2025 FTC interim report documented the mechanics of this dynamic in detail. Pharmacies affiliated with the three largest PBMs accounted for nearly 70 percent of all specialty drug revenues. The FTC found evidence that PBMs were steering highly profitable prescriptions to their own affiliated pharmacies and away from unaffiliated pharmacies, to the tune of $7.3 billion above the drug cost.

The steering mechanism works through formulary design. PBMs design drug formularies that favor medications dispensed by PBM-affiliated pharmacies, increasing the likelihood that patients will be directed to these pharmacies for high-cost specialty medications. The steering is reinforced through reimbursement differentials: PBM-affiliated pharmacies were paid 20 to 40 times the National Average Drug Acquisition Cost for specific specialty generics, while independent pharmacies receive significantly less for the same drugs.

For a patient, this plays out as a limited specialty pharmacy network that excludes the independent pharmacy their practice has a relationship with, or a prior authorization that is processed faster when the prescription routes through the PBM's own dispensing arm. The clinical relationship between the practice and the patient gets interrupted by a financial architecture the patient never agreed to and almost certainly does not understand.

Wholesalers are following the same playbook

The PBM consolidation wave is not the only vertical integration story in the drug supply chain right now. Pharmaceutical wholesalers are adopting vertical integration strategies similar to PBMs, expanding into physician practice management and specialty drug administration.

The PBM model began as a service function, primarily processing claims, negotiating rebates, and managing formularies on behalf of health plans and employers. But over time, PBMs and their affiliated insurers expanded their reach, acquiring or building their own specialty pharmacies and mail-order operations. Wholesalers are now replicating that trajectory. They began as distribution infrastructure and are moving into care delivery, capturing higher-margin services tied to drug administration.

Wholesalers' integration into care delivery raises concerns about transparency, competition, and potential influence over drug utilization and site-of-care decisions. The concern is the same one that took years to fully surface in the PBM context: when the entity that distributes a drug also influences where and how it is administered, the conflict of interest is structural, not incidental.

The hospital specialty pharmacy expansion

The consolidation is also moving into hospital systems from a different direction. Changes in manufacturers' 340B contract pharmacy policies have accelerated hospitals' investments in in-house specialty pharmacy operations.

The large integrated players are moving into this space aggressively. Cigna's Evernorth Health Services now owns 100 percent of CarepathRx, which assists hospitals and health systems with specialty pharmacy operations. In 2025, Evernorth also invested $3.5 billion for an undisclosed stake in Shields Health Solutions. In 2024, UnitedHealth Group acquired CPS Solutions, which also offers specialty pharmacy services to hospitals and health systems.

The practical effect is that hospital-based specialty pharmacy operations, which were once more independent of the large PBMs, are now increasingly owned or supported by the same entities that manage the benefit side of the equation. The integration is moving in all directions simultaneously.

What the regulatory response looks like right now

The regulatory pressure on vertical integration has reached a level that was not present two years ago. Whether that pressure produces structural change is a different question, but the direction of attention is clear.

At the federal level, the Break Up Big Medicine Act was introduced with bipartisan support in April 2026. The proposal would bar common ownership of insurers or PBMs with medical providers or management services organizations, aiming to eliminate vertically integrated steering and self-dealing incentives. Noncompliance after one year would trigger automatic remedies, including profit disgorgement and compelled asset sales to unwind prohibited corporate structures. The bill cites the same market concentration data that has been building in FTC reports: three PBMs adjudicating approximately 80 percent of claims and three wholesalers controlling approximately 98 percent of drug distribution.

At the state level, the approaches have been more varied and have run into their own complications. Arkansas enacted a law in 2025 that bans PBMs from owning or operating retail or mail-order pharmacies, targeting vertical integration and self-dealing where PBMs steer patients to their own facilities. The reform hit a snag when a federal judge issued a preliminary injunction in July 2025, citing constitutional concerns including potential violations of the Commerce Clause and conflicts with federal programs.

Vertical integration scrutiny is intensifying, with proposals to restrict joint ownership across insurers, PBMs, providers, and wholesalers to mitigate formulary steering and conflicts of interest. Whether the legislative momentum translates into enacted law in 2026 is not settled. What is settled is that the policy conversation has moved from questioning whether the problem exists to debating what structural remedies are proportionate.

What this means for specialty access on the ground

The consolidation of the PBM market has access consequences that are immediate and operational, not just structural and theoretical.

Specialty pharmacy networks get narrower as more dispensing volume routes through affiliated pharmacies. A practice that has built a relationship with an independent specialty pharmacy that knows their patient population, their clinical protocols, and their prior authorization workflows may find that relationship disrupted by a formulary change they had no input into.

Prior authorization criteria increasingly reflect the interests of the integrated system, not just the clinical evidence. When the entity writing the PA criteria also profits from which pharmacy fills the prescription, the criteria are not neutral.

PAP and copay assistance programs can be disrupted by PBM formulary decisions. When a PBM moves a specialty medication to a non-preferred tier or excludes it entirely in favor of a drug with a larger rebate, the access infrastructure built around that medication, the PAP enrollment, the patient support program, the hub services, all of it becomes less useful overnight.

Independent specialty pharmacies, which often provide a level of patient support and access navigation that affiliated pharmacies do not replicate, are being squeezed out of networks through the reimbursement differential documented in the FTC report. The practices and patients who relied on those relationships are absorbing the loss without understanding why it happened.

The question that does not have a clean answer yet

The argument made by integrated systems is that consolidation enables cost savings, data sharing, and care coordination that fragmented markets cannot. Proponents of vertical integration argue that owning a PBM and pharmacies could allow a health plan to access data about net prices of drugs and beneficiaries' behaviors that would not generally be available from external vendors. The argument is not absurd. Integration can create efficiencies.

What the FTC data suggests, and what the operational experience of specialty practices confirms, is that the efficiency argument has not translated into access improvement for patients on specialty medications. The savings, where they exist, have not flowed to plan sponsors and patients. The data integration has produced steering, not coordination. The consolidated market has produced higher prices for specialty generics at affiliated pharmacies, not lower ones.

The reform proposals now in circulation, from the Break Up Big Medicine Act at the federal level to state-level bans on PBM pharmacy ownership, reflect a judgment that the integration model has not delivered on its stated rationale. Whether those reforms survive legal challenge and become law is the question that will shape the next several years of the specialty access landscape.

The consolidation of PBMs, payers, and specialty pharmacies is not a background structural fact. It is the active mechanism by which access decisions get made for specialty patients. Understanding the architecture is not optional for anyone building or operating inside the space.

What practices need to understand right now

The vertical integration landscape is not stable. The regulatory environment is the most active it has been in years, and the legislative proposals on the table, if enacted, would force structural unwinding of some of the largest entities in the drug supply chain.

In the meantime, the practices most exposed are those that have not paid attention to which specialty pharmacies are inside their patients' networks, which PBMs are processing their prior authorizations, and how the affiliated pharmacy relationships of those PBMs affect the access pathways they have built.

The practices best positioned are the ones that understand the system well enough to navigate it as it currently exists while watching the regulatory horizon closely enough to anticipate where it is going.

That is not easy. It requires the kind of operational fluency and policy awareness that most specialty practices do not have dedicated infrastructure to maintain. But the alternative, operating inside this system without understanding it, is how practices lose patients to access failures they could have anticipated.

Taylor McKinney · The Access Gap · @theaccessgap